Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-25-01003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Marco Maria Germani und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Human epidermal growth factor receptor 2 (HER2) amplification/overexpression (HER2-pos) is detected in 5% of RAS/BRAF wild-type metastatic colorectal cancers (mCRCs). Its prognostic/predictive role in terms of benefit from anti-EGFR/bevacizumab (bev) is debated. Similarly, the role of activating HER2 mutations (mut) is unclear. METHODS We collected individual data of 1,604 patients with proficient mismatch repair (pMMR)/microsatellite stable (MSS) RAS/BRAF wild-type untreated mCRC with HER2 amplification/expression status available enrolled in eight randomized clinical trials (RCT; TRIBE2, TRIPLETE, VALENTINO, ATEZOTRIBE, PANDA, PANAMA, PARADIGM, and CALGB/SWOG80405). Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were assessed with respect to HER2 amplification/expression and HER2 mutational status and according to biologics (anti-EGFR/bev). RESULTS Patients with HER2-pos were 81 (5%). HER2-pos patients experienced shorter PFS (median PFS [mPFS]: 9.8 v 12.2 months, hazard ratio [HR], 1.31, P = .02) and OS (median OS [mOS]: 28.0 v 34.9 months, HR, 1.37, P = .01), also after adjustment for covariates ( P adj PFS = .02, P adj OS = .048). ORR was similar between HER2-pos and HER2-negative (HER2-neg) tumors (75% v 72%, odds ratio [OR], 1.21, P = .47). We found no interaction between HER2 amplification/expression status and biologics' effect in terms of PFS ( P int = .76), OS ( P int = .76), and ORR ( P int = .64). In left-sided HER2-pos tumors, outcomes were similar with chemotherapy plus bev/anti-EGFRs in terms of PFS (9.8 v 9.3 months, HR, 0.73, P = .29), OS (29.8 v 28.0 months, HR, 1.29, P = .40), and ORR (59% v 79%, OR, 0.39, P = .10). HER2 -mutant tumors (2% of patients with HER2-neg tumors) showed shorter OS than HER2 wild-type ones (mOS: 23.7 v 34.4 months, HR, 1.56, P = .04) with no differential effect of biologics ( P int ORR = .81; P int PFS = .95; P int OS = .92). CONCLUSION To our knowledge, this is the largest analysis of HER2 status in patients with untreated mCRC enrolled in RCT. Waiting for targeted approaches, HER2-pos and mut do not predict benefit from bev/anti-EGFRs and should be regarded as negative prognostic factors in pMMR/MSS RAS/BRAF wild-type mCRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Medical Oncology Department, Fondazione IRCCS-Istituto Nazionale dei Tumori, Milan, Italy.
- USC Norris Comprehensive Cancer Center, Los Angeles, CA.
- Oncology 1, IOV-Istituto Oncologico Veneto IRCCS, Padova, Italy.
ORCID-Profile: Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Francesca Battaglin, Francesca Bergamo, Lisa Salvatore, Arndt Stahler, Carlotta Antoniotti, Kohei Shitara, Alan Venook, Eiji Oki, Kei Muro, Junpei Soeda, Sara Lonardi, Filippo Pietrantonio, Heinz-Josef Lenz, Dominik Paul Modest, Takayuki Yoshino, Chiara Cremolini
Förderung
- NCI NIH HHS
Zitieren
APA
Germani, M. M., Borelli, B., Hashimoto, T., Nakamura, Y., Oldani, S., Battaglin, F., Bergamo, F., Salvatore, L., Stahler, A., Antoniotti, C., Shitara, K., Venook, A., Oki, E., Muro, K., Ugolini, C., Soeda, J., Lonardi, S., Pietrantonio, F., Lenz, H. J., …, & Cremolini, C. (2025). Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01003
Vancouver
Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, et al. Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-01003
BibTeX
@article{Germani2025,
author = {Germani, Marco Maria and Borelli, Beatrice and Hashimoto, Tadayoshi and Nakamura, Yoshiaki and Oldani, Simone and Battaglin, Francesca and Bergamo, Francesca and Salvatore, Lisa and Stahler, Arndt and Antoniotti, Carlotta and Shitara, Kohei and Venook, Alan and Oki, Eiji and Muro, Kei and Ugolini, Clara and Soeda, Junpei and Lonardi, Sara and Pietrantonio, Filippo and Lenz, Heinz-Josef and Modest, Dominik Paul and Yoshino, Takayuki and Cremolini, Chiara},
title = {Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-25-01003}
}
EUVIMED